TEK and neoplasm: Although Ang2 is only weakly expressed in quiescent ECs under physiological conditions, its expression—along with Tie2—is dramatically upregulated in hypoxia, which is a hallmark of the tumor microenvironment, making Ang2 an attractive candidate for anti-angiogenic therapies.